TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03027791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Sessions
Description: 12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
Study: NCT03763565

Intervention type: BIOLOGICAL
Intervention: Bivalent or Quadrivalent HPV vaccines
Description: Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years

Intervention type: OTHER
Intervention: Control group
Description: Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
Study: NCT03349398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y reconstruction
Description: Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y reconstruction
Description: Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
Study: NCT00933218

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: polyphenols (non-alcoholic beer)
Description: 1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beverage without polyphenols
Description: 1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
Study: NCT00978822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine butyrate injectable emulsion
Description: Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
Study: NCT04495647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation
Description: Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention.
Study: NCT02266108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTIMA Intervention
Description: This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ESTIMA Intervention
Description: This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
Study: NCT04225325

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SYMTUZA
Description: DESCOVY+REZOLSTA
Study: NCT04495647

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Body Electromyostimulation
Description: Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Body Electromyostimulation
Description: Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention.
Study: NCT04225325

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: DESCOVY+DOLUTEGRAVIR
Description: DESCOVY+DOLUTEGRAVIR

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SYMTUZA+DOLUTEGRAVIR
Description: DESCOVY+REZOLSTA+DTG
Study: NCT02840331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort
Description: Single oral doses (900 milligram) 2-4 hours before laparoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic diagnostic and therapy
Description: Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
Study: NCT01884792

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sitting OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting OGTT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standing OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing OGTT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sitting CGM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting CGM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standing CGM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing CGM
Study: NCT00686816

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low calorie diet
Description: low calorie diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olestra
Description: low calorie Olestra diet
Study: NCT00428402

Intervention type: BEHAVIORAL
Intervention: Focus Group Discussion
Description: Focus groups meeting for up to 1 hour during the regular school day.
Study: NCT01147614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)
Description: BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Specialty mental health care referral (SMHC)
Description: SMHC: specialty mental health care referrals provided
Study: NCT00576979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT02791880

Intervention type: PROCEDURE
Intervention: Transcatheter Aortic Valve Replacement
Description: The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
Study: NCT04997122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive pomace oil
Description: Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High oleic acid sunflower oil
Description: Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
Study: NCT01735409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX + DDP
Description: ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX + DDP
Description: ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX + DDP
Description: ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
Study: NCT03586726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
Study: NCT01121276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study: NCT02147925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide combined with metformin
Description: Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine combined with metformin
Description: The initial dose will be 0.2 unit/kg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin combined with metformin
Description: The dose throughout the study will be 100mg per day.
Study: NCT03226522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03958422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardiomyopeptidin
Description: The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
Study: NCT03616990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASC Service Linkages - Discharge Area Only
Description: Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TASC Service Linkages - Discharge Area Only
Description: Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SRC Overnight Stay
Description: Individuals receiving SRC services will have the option to stay at the SRC overnight. At the SRC, individuals will be able to rest, have a meal, receive a change of clothes, and take a shower in a therapeutic, non-coercive environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASC Services Linkages - SRC Onsite
Description: While at the SRC, individuals will meet with TASC Care Coordinators. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APN Appointment
Description: Individuals at the SRC will be able to meet with an Advanced Practice Nurse. As part of that visit, the APN will be able to prescribe medications or reroute prescriptions previously administered by the Cook County Jail's hospital, Cermak, to a participant's desired location as needed.
Study: NCT01066182

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid)
Description: 3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil capsules
Description: The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
Study: NCT01866319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 10 mg/kg IV, administered Q2W or Q3W based upon randomization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 10 mg/kg IV, administered Q2W or Q3W based upon randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg IV Q3W.
Study: NCT04192006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Surgical implantation of prosthetic knee using robotic-arm assist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Surgical implantation of prosthetic knee using robotic-arm assist
Study: NCT02972047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: Subjects in this are practice diaphragmatic breathing for 30 minutes after each meal.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham therapy (listening to music/watching TV for 30 minutes after each meal
Study: NCT01482377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5479599
Description: RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5479599
Description: RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5479599
Description: RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5479599
Description: RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m\^2 for the first infusion, followed by doses of 250 mg/m\^2 for subsequent infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib, at a dose of 150 mg will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zirconium-89-labeled RO5479599
Description: Single dose of radiolabeled drug will be administered.
Study: NCT00886275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, Midazolam
Description: The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
Study: NCT01805583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: workplace intervention (WPI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: workplace intervention (WPI)
Study: NCT01759940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0,375%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0,75%
Study: NCT01900080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-Day HIV testing and ART initiation
Description: Same-day HIV testing and ART initiation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART Initiation
Description: Standard ART Initiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-Study: Same-Day ART, CD4 Count >500
Description: Same-day CD4 count and ART initiation for patients with CD4 count \>500 cells/mm3 (CD4 count within 7 days of HIV test)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Study: Standard Pre-ART Care, CD4 Count >500
Description: Standard pre-ART care for patients with CD4 count \>500 cells/mm3
Study: NCT00388544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity matched to interest
Description: Recreational activities are tailored to subject's style of interest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity matched to function
Description: Recreational activities are tailored to subjects physical and cognitive functioning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity matched to both interest and function
Description: Recreational activities are tailored to both style of interest and physical and cognitive functioning.
Study: NCT04000100

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound- guided supraclavicular brachial plexus block
Description: Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound- guided supraclavicular brachial plexus block
Description: Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure